Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (99)
Australian Public Assessment Report (AusPAR) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (11)
2015 (8)
2014 (8)
2013 (14)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1994 (1)
1993 (3)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

225 result(s) found, displaying 81 to 90

MPL-HYDROMORPHONE hydromorphone hydrochloride 4mg tablet bottle Cancelled under Section 30(1)(c) of the Act

29 October 2021

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-HYDROMORPHONE hydromorphone hydrochloride 2 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

29 October 2021

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 0.7/0.18 buprenorphine (as HCl) 0.7 mg / naloxone (as HCl dihydrate) 0.18 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 1.4/0.36 buprenorphine (as HCl) 1.4 mg / naloxone (as HCl dihydrate) 0.36 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 2.9/0.71 buprenorphine (as HCl) 2.9 mg / naloxone (as HCl dihydrate) 0.71 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 5.7/1.4 buprenorphine (as HCl) 5.7 mg / naloxone (as HCl dihydrate) 1.4 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 8.6/2.1 buprenorphine (as HCl) 8.6 mg / naloxone (as HCl dihydrate) 2.1 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 11.4/2.9 buprenorphine (as HCl) 11.4 mg / naloxone (as HCl dihydrate) 2.9 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
AusPAR: Pralatrexate

22 August 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Pralatrexate
AusPAR: Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride)

24 September 2020

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride)

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.